IL256069B1 - Adenovirus polynucleotides and polypeptides - Google Patents

Adenovirus polynucleotides and polypeptides

Info

Publication number
IL256069B1
IL256069B1 IL256069A IL25606917A IL256069B1 IL 256069 B1 IL256069 B1 IL 256069B1 IL 256069 A IL256069 A IL 256069A IL 25606917 A IL25606917 A IL 25606917A IL 256069 B1 IL256069 B1 IL 256069B1
Authority
IL
Israel
Prior art keywords
polypeptides
adenovirus
polynucleotides
adenovirus polynucleotides
Prior art date
Application number
IL256069A
Other languages
Hebrew (he)
Other versions
IL256069A (en
IL256069B2 (en
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510357.5A external-priority patent/GB201510357D0/en
Priority claimed from PCT/EP2015/063248 external-priority patent/WO2015189425A1/en
Priority claimed from GBGB1514772.1A external-priority patent/GB201514772D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of IL256069A publication Critical patent/IL256069A/en
Publication of IL256069B1 publication Critical patent/IL256069B1/en
Publication of IL256069B2 publication Critical patent/IL256069B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL256069A 2015-06-12 2017-12-03 Adenovirus polynucleotides and polypeptides IL256069B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1510357.5A GB201510357D0 (en) 2015-06-12 2015-06-12 Adenovirus polynucleotides and polypeptides
PCT/EP2015/063248 WO2015189425A1 (en) 2014-06-13 2015-06-12 Immunogenic combinations
GBGB1514772.1A GB201514772D0 (en) 2015-08-19 2015-08-19 Adenovirus polynucleotides and polypeptides
PCT/EP2016/063329 WO2016198621A1 (en) 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides

Publications (3)

Publication Number Publication Date
IL256069A IL256069A (en) 2018-01-31
IL256069B1 true IL256069B1 (en) 2023-03-01
IL256069B2 IL256069B2 (en) 2023-07-01

Family

ID=57503533

Family Applications (2)

Application Number Title Priority Date Filing Date
IL256069A IL256069B2 (en) 2015-06-12 2017-12-03 Adenovirus polynucleotides and polypeptides
IL256121A IL256121B2 (en) 2015-06-12 2017-12-05 Adenovirus polynucleotides and polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL256121A IL256121B2 (en) 2015-06-12 2017-12-05 Adenovirus polynucleotides and polypeptides

Country Status (13)

Country Link
US (4) US11254710B2 (en)
EP (2) EP3307313A1 (en)
JP (2) JP6983665B2 (en)
KR (2) KR20180012857A (en)
CN (2) CN108025058B (en)
AU (4) AU2016275619B2 (en)
BE (1) BE1024420B1 (en)
BR (1) BR112017026523A2 (en)
CA (2) CA2988481A1 (en)
EA (1) EA038402B9 (en)
IL (2) IL256069B2 (en)
MX (2) MX2017016105A (en)
WO (2) WO2016198599A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307313A1 (en) 2015-06-12 2018-04-18 GlaxoSmithKline Biologicals SA Adenovirus polynucleotides and polypeptides
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
BR112019010275A2 (en) * 2016-12-09 2019-09-17 Glaxosmithkline Biologicals Sa recombinant adenovirus, composition, use of adenovirus or composition, method of inducing an immune response in a patient, and non-human simian adenovirus
EP3655539A1 (en) 2017-07-21 2020-05-27 GlaxoSmithKline Biologicals S.A. Chikungunya virus antigen constructs
AU2018351308B2 (en) 2017-10-16 2021-12-02 Glaxosmithkline Biologicals Sa Replication competent adenoviral vectors
CN111527213A (en) 2017-10-16 2020-08-11 葛兰素史密丝克莱恩生物有限公司 Adenovirus vectors with two expression cassettes encoding RSV antigenic proteins or fragments
US20200299651A1 (en) 2017-10-16 2020-09-24 Glaxosmithkline Biologicals Sa Simian adenoviral vectors with two expression cassettes
MX2020003389A (en) 2017-10-16 2022-08-04 Glaxosmithkline Biologicals Sa Enhanced promoter.
CA3078685A1 (en) * 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
MX2020006225A (en) 2017-12-20 2020-12-07 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen constructs.
MX2020013553A (en) * 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides.
US20210277417A1 (en) * 2018-06-25 2021-09-09 Akouos, Inc. Methods of treating clrn1-associated hearing loss and/or vision loss
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
EP3810277A1 (en) * 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
JP2021533162A (en) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Processes and vaccines
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
EP4150344A1 (en) 2020-05-14 2023-03-22 GlaxoSmithKline Biologicals SA Viral biosensors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105084A2 (en) * 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
JP2012516679A (en) * 2009-02-02 2012-07-26 オカイロス アーゲー Nucleic acid and amino acid sequences of simian adenovirus, vectors containing the same, and uses thereof
WO2013052799A2 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vectors and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
CA2451864C (en) 2001-06-22 2013-01-15 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
NZ564586A (en) * 2001-11-21 2009-09-25 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7030094B2 (en) 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7205342B2 (en) * 2003-10-10 2007-04-17 General Electric Company Poly(arylene ether) composition and method of molding
ES2871907T3 (en) * 2004-01-23 2021-11-02 Msd Italia Srl Chimp adenovirus vaccine carriers
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
CN102220357B (en) * 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 Multivalent vaccines comprising recombinant viral vectors
KR101451620B1 (en) * 2005-05-12 2014-10-21 글락소 그룹 리미티드 Vaccine composition
CA2610919C (en) * 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
PT2137210T (en) 2007-03-02 2017-01-09 Glaxosmithkline Biologicals Sa Novel method and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
JP5740157B2 (en) * 2007-11-28 2015-06-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Monkey subfamily B adenovirus SAdV-28, -27, -29, -32, -33 and -35 and their uses
AU2008331906B2 (en) * 2007-11-28 2014-03-06 The Trustees Of The University Of Pennsylvania Simian E adenovirus SAdV-39
CA2716928C (en) * 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
JP2011521985A (en) 2008-06-03 2011-07-28 オカイロス アーゲー Vaccine for prevention and treatment of HCV infection
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
EP2435559A1 (en) * 2009-05-29 2012-04-04 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
AU2010278797A1 (en) * 2009-07-31 2012-03-15 Paxvax, Inc. Adenoviral-based vectors
WO2011130627A2 (en) * 2010-04-16 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimpanzee adenoviral vector-based filovirus vaccines
BR112012029912A2 (en) 2010-05-26 2016-11-16 Selecta Biosciences Inc Synthetic Nanotransport Combination Vaccines
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US20120328605A1 (en) 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
FR2978457A1 (en) * 2011-07-27 2013-02-01 Univ Paris Diderot Paris 7 New compound comprising a nucleic acid having a specified sequence and encoding a polypeptide having a specified sequence or a polypeptide having a specified sequence, useful for treating atherosclerosis and cardiac hypertrophy
CN103239734B (en) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 For preventing and/or treating the vaccine of respiratory syncytial virus infection
CA2867955C (en) 2012-03-22 2023-02-07 Crucell Holland B.V. Vaccine against rsv
MY171498A (en) 2012-08-01 2019-10-15 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
MX2015006377A (en) 2012-11-20 2015-07-21 Glaxosmithkline Biolog Sa Rsv f prefusion trimers.
DE102012221236A1 (en) 2012-11-21 2014-05-22 Zf Friedrichshafen Ag transmission
GB201303406D0 (en) * 2013-02-26 2013-04-10 Health Prot Agency Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition
EA032326B1 (en) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Gla monotherapy for use in cancer treatment
CN103937835A (en) * 2013-08-19 2014-07-23 中国科学院上海巴斯德研究所 Expression vector based on adenovirus AdC68 and construction method thereof
CN103923943B (en) * 2013-08-19 2019-01-22 中国科学院上海巴斯德研究所 A kind of expression vector and its construction method based on adenovirus AdC7
GB201318084D0 (en) * 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
EP3307313A1 (en) 2015-06-12 2018-04-18 GlaxoSmithKline Biologicals SA Adenovirus polynucleotides and polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105084A2 (en) * 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
JP2012516679A (en) * 2009-02-02 2012-07-26 オカイロス アーゲー Nucleic acid and amino acid sequences of simian adenovirus, vectors containing the same, and uses thereof
WO2013052799A2 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vectors and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, DANHER, ET AL., A COMPLEX ADENOVIRUS VACCINE AGAINST CHIKUNGUNYA VIRUS PROVIDES COMPLETE PROTECTION AGAINST VIRAEMIA AND ARTHRITIS., 30 November 2011 (2011-11-30) *

Also Published As

Publication number Publication date
WO2016198599A1 (en) 2016-12-15
US20220204566A1 (en) 2022-06-30
EA201792651A1 (en) 2018-06-29
US20180170972A1 (en) 2018-06-21
AU2016275619B2 (en) 2019-09-19
AU2019271972B2 (en) 2022-03-31
CN107921118A (en) 2018-04-17
CN108025058A (en) 2018-05-11
US11254710B2 (en) 2022-02-22
AU2016275601A1 (en) 2018-01-18
EP3307314A1 (en) 2018-04-18
AU2019271972A1 (en) 2019-12-19
CA2988481A1 (en) 2016-12-15
EA038402B9 (en) 2021-09-22
IL256069A (en) 2018-01-31
IL256121A (en) 2018-02-28
CN107921118B (en) 2022-11-08
AU2019202081B2 (en) 2021-09-23
BE1024420A1 (en) 2018-02-12
AU2016275619A1 (en) 2018-01-04
EA038402B1 (en) 2021-08-23
IL256121B2 (en) 2023-02-01
IL256121B (en) 2022-10-01
US20220220157A1 (en) 2022-07-14
KR20180011265A (en) 2018-01-31
KR20180012857A (en) 2018-02-06
JP6983665B2 (en) 2021-12-17
MX2017016101A (en) 2018-02-21
JP2018524977A (en) 2018-09-06
US11254711B2 (en) 2022-02-22
CA2988654A1 (en) 2016-12-15
BR112017026523A2 (en) 2018-08-14
JP2018523980A (en) 2018-08-30
KR102535670B1 (en) 2023-05-22
AU2019202081A1 (en) 2019-04-18
JP6873054B2 (en) 2021-05-19
IL256069B2 (en) 2023-07-01
MX2017016105A (en) 2018-05-15
US20200140886A1 (en) 2020-05-07
WO2016198621A1 (en) 2016-12-15
BE1024420B1 (en) 2018-02-19
EP3307313A1 (en) 2018-04-18
CN108025058B (en) 2022-12-16

Similar Documents

Publication Publication Date Title
IL256121B (en) Adenovirus polynucleotides and polypeptides
IL275307B (en) Syntac polypeptides and uses thereof
IL266942A (en) Adenovirus polynucleotides and polypeptides
ZA201802261B (en) Polypeptides
IL274217A (en) Adenovirus and uses thereof
IL274219A (en) Adenovirus and uses thereof
HK1250041A1 (en) Polypeptides
GB201713765D0 (en) Modified adenovirus
ZA201704366B (en) Il-17a-binding polypeptides
HK1250040A1 (en) Polypeptides
IL274220A (en) Adenovirus and uses thereof
IL258897A (en) Polypeptides against il-23
GB201410031D0 (en) Polypeptides and uses thereof
ZA201708159B (en) Adenovirus polynucleotides and polypeptides
GB201514772D0 (en) Adenovirus polynucleotides and polypeptides
GB201510357D0 (en) Adenovirus polynucleotides and polypeptides
GB201614607D0 (en) Modified adenovirus
GB201706219D0 (en) Modified adenovirus
GB201700663D0 (en) Modified adenovirus
GB201511958D0 (en) Polypeptides, polynucleotides and uses thereof
GB201613142D0 (en) Polypeptides and uses thereof
GB201613143D0 (en) Polypeptides and uses thereof